Community post

Intralytix is recruiting patients for its Crohn's disease clinical trial out of Mount Sinai Hospital in New York. They will be evaluating patient stool samples for presence of adherent invasive E. coli (AIEC), and if positive, patients will be treated with phages that target AIEC strains.